Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma

14th February 2025 Uncategorised 0

Bristol Myers Squibb is striking out in its attempts to broaden the label of its first-in-class combo drug Opdualag. On Thursday, the company revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected state III and stage IV melanoma did not achieve its primary endpoint.

More: Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Source: fierce